Medical Device Network on MSN
Synchrony Medical bolsters US COPD treatment commercialisation with $5m funding round
Synchrony Medical's LibAirty system for addressing mucus obstruction in COPD patients gained FDA clearance in July 2025.
Mepolizumab reduces moderate to severe COPD exacerbations in patients with varying blood eosinophil counts and type 2 inflammation.
Results showed that a dry powder inhaler loaded with umeclidinium and vilanterol produced a 14% lower risk of moderate or severe COPD flare-ups, compared to a metered-dose inhaler loaded with ...
Inhaled maintenance therapy is underused among hospitalized patients with COPD in China, even in those with frequent prior hospitalizations.
Asthma and COPD share similar breathing symptoms, often leading to confusion and misdiagnosis. Know key differences, risks of ...
Both dupilumab and mepolizumab were originally approved for asthma but were subsequently studied in patients with COPD who continue to experience symptoms and moderate-to-severe exacerbations despite ...
Recent medical research is reshaping our understanding of Chronic Obstructive Pulmonary Disease (COPD), particularly highlighting its disproportionate impact on women. This shift in the COPD landscape ...
Recent research suggests that certain biologic medications called monoclonal antibodies may help treat emphysema more effectively than some current therapies. These medications include benralizumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results